Ribo Newsroom
-
The clinical application of Suzhou Ribo for new drug for treatment of type 2 diabetes got accepted by CDERecently, Center for Drug Evaluation, National Medical Products Administration officially accepted the clinical trial application of imported drug ISIS449884 Injection submitted by Suzhou Ribo Life Science Co. Ltd.,. This product belongs to Class 1 innovative drug not marketed in China or abroad, and the proposed indication is type 2 diabetes.July 12, 2018 -
Phase II/III study of optic neuroprotective oligonucleotide therapeutics QPI-1007 completed dosing of the first subject in ChinaKunshan RiboQuark Pharmaceutical Technology Co. Ltd. announced that in the global pivotal II/III study QRK207 of its innovative siRNA drug QPI-1007 for optic nerve protection, the investigational product has been administered to the first subject by Professor Wang Ningli's team at Beijing Tongren Hospital, Capital Medical University, China.November 13, 2017 -
Ribo successfully raised 270 million yuan in its Series B financingOn April 21, 2017, Suzhou Ribo Life Science Co., Ltd. announced the successful completion of Series B private equity financing of RMB 270 million (about $40 million), which introduced strong capital support for developing China's oligonucleotide pharmaceutical industry.April 21, 2017 -
Ribo launched a strategic collaboration with global oligonucleotide pharmaceutical giant, Ionis, USASuzhou Ribo Life Science Co. Ltd., announced today a partnership with the global oligonucleotide pharmaceutical giant Ionis Pharmaceutical Inc. (Nasdaq code: IONS). Furthermore, it signed cooperation and licensing agreements to work together to promote the R&D and commercialization of oligonucleotide pharmaceuticals (or RNA-targeted drugs) in CApril 18, 2017